GHRP-2: A Literature Course on What the Published Studies Report

This course organises the published GHRP-2 literature into six modules: what the compound is, how its mechanism has been described, what individual studies reported, what adverse events appear in print, what pharmacokinetic data exist, and how the compound is classified by regulators. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, diagnosis or treatment. Nothing here is a protocol, a recommendation, or a statement that any outcome would occur in any person.

A note on method: each claim below is tied to a specific paper in the same sentence, and results are described only as far as the cited study itself reported them. Where the verified literature does not contain a number, no number is given rather than estimated.

Module 1: What GHRP-2 Is and How It Has Been Studied

Definition and class

GHRP-2 is a synthetic peptide belonging to the class known as growth hormone secretagogues — small molecules and peptides developed to trigger pituitary growth hormone (GH) release through a pathway separate from GH-releasing hormone. A 2004 development profile in Drugs in R&D catalogued the compound under the generic name pralmorelin and the development codes GHRP-2, GPA-748 and KP-102, describing it as a potent growth hormone-releasing peptide taken through pharmaceutical development (PMID 15230633).

Origin and naming

The same 2004 profile listed several formulation-specific codes, including KP-102 D and KP-102 LN, reflecting that more than one presentation of the peptide was pursued during development (PMID 15230633). In the clinical literature the peptide most often appears under the pralmorelin name when used as a pituitary test agent, and under "GHRP-2" in physiology and animal work — for example a 2022 study in the Journal of the Endocrine Society that examined the clinical usefulness of the GHRP-2 test in patients with hypothalamic-pituitary disorder (PMID 35795807).

Forms that appear in studies

• Injectable peptide for provocative testing. Human diagnostic studies administered GHRP-2 as a test agent and measured the resulting pituitary hormone response, as in the 2022 hypothalamic-pituitary disorder study (PMID 35795807) and a 2018 Endocrine Journal evaluation of GHRP-2 for the diagnosis of thyrotropin-producing pituitary adenomas (PMID 29973439).
• Research peptide in animal and cell models. GHRP-2 was applied to mouse pituitary tissue in a 2009 Regulatory Peptides study of adrenocorticotropic hormone (ACTH) secretion and synthesis (PMID 19682503) and to human ovarian granulosa cells in a 2016 in vitro inflammation study (PMID 27548147).
• Chemically modified analogues. A 2015 AAPS PharmSciTech paper described the synthesis of a mono-PEGylated GHRP-2 and the investigation of its biological activity, meaning the molecule has also been studied as a starting scaffold rather than only as-is (PMID 25761386).

Limits of the evidence in Module 1

The verified literature identifies GHRP-2 chemically and by development code, but it does not establish an approved therapeutic indication, and it does not describe long-term human use. The papers available here are diagnostic studies, mechanistic animal and cell studies, a formulation study and a development profile — not a body of long-duration treatment trials.

Module 2: Mechanism as Described in the Literature

A ghrelin-like signal at the pituitary

GHRP-2 is generally discussed alongside ghrelin, the endogenous hormone that acts at the growth hormone secretagogue receptor. A 2005 study in the Journal of Clinical Endocrinology and Metabolism framed this directly in its title, reporting that GHRP-2, like ghrelin, increased food intake in healthy men (PMID 15699539). A 2002 European Journal of Pharmacology study likewise compared chicken ghrelin and GHRP-2 side by side in neonatal chicks (PMID 12393062), reinforcing that researchers have treated the peptide as a pharmacological stand-in for ghrelin receptor activation.

GH release that does not depend on an intact GHRH signal

One of the clearest mechanistic questions in the literature is whether GHRP-2 can drive GH release when GH-releasing hormone signalling is impaired. A 2012 study in Clinics addressed this by measuring the GH response to GHRP-2 in growth hormone-deficient little mice, a strain used precisely because its GH axis is genetically compromised (PMID 22473409). In humans, the diagnostic literature rests on the same logic: the 2022 study evaluated how informative the GH response to GHRP-2 was for classifying hypothalamic-pituitary disorder (PMID 35795807).

Effects beyond growth hormone

The pituitary is not a single-hormone organ, and the literature reflects that. Researchers reported that GHRP-2 stimulated both the secretion and the synthesis of ACTH in mouse pituitary (PMID 19682503), and a 2018 evaluation examined thyrotropin responses to GHRP-2 in the setting of thyrotropin-producing pituitary adenomas (PMID 29973439). Conversely, a 2010 Endocrine Journal study reported that GH-releasing peptide-2 did not stimulate arginine vasopressin secretion in healthy men (PMID 19907099), which is a useful example of a published negative result narrowing a mechanism rather than widening it.

Signalling outside the pituitary

At least one paper examined non-pituitary tissue: the 2016 in vitro study reported that GHRP-2 attenuated protein kinase C-induced inflammation in human ovarian granulosa cells (PMID 27548147). That is a cell-culture observation about a signalling pathway, not a demonstration of any clinical anti-inflammatory effect.

Limits of the evidence in Module 2

Mechanism in this set is inferred from endpoint measurements — hormone concentrations, food intake, inflammatory markers in cells — rather than from receptor occupancy studies in humans. Species differences are explicit: the direction of the feeding response reported in men (PMID 15699539) was opposite to that reported in neonatal chicks (PMID 12393062), so mechanism cannot be generalised across species without care.

Module 3: Reported Outcomes by Study

The table below lists each verified study by model and endpoint, with the outcome as the paper itself reported it. No benefit is implied, and none of these outcomes has been shown to carry over to any other setting.

Limits of the evidence in Module 3

Most human entries in this table are single-administration diagnostic or physiology studies with hormonal or appetite endpoints. None of them measured body composition over time, athletic performance, injury recovery, or ageing outcomes, and none followed participants for months or years. An outcome reported once, in one model, is a hypothesis — not an established effect.

Module 4: GHRP-2 Side Effects: What Studies Report

The verified literature does not contain a systematic, pooled adverse-event catalogue for GHRP-2. What it does contain is a formal general pharmacology assessment, a development monograph, and several studies whose measured endpoints double as potential unwanted effects.

Safety pharmacology and development reporting

A 2004 Arzneimittelforschung paper set out the general pharmacology of KP-102 (GHRP-2), the type of broad organ-system screening conducted during preclinical development to look for effects outside the intended target (PMID 15646371). The 2004 Drugs in R&D profile summarised the compound's development history and status under its various code names (PMID 15230633). Readers evaluating tolerability should read those two source abstracts directly rather than rely on any secondary summary, including this one.

Endocrine effects beyond GH

Because GHRP-2 is not GH-selective, effects on other pituitary hormones are relevant. Researchers reported that GHRP-2 stimulated ACTH secretion and synthesis in mouse pituitary (PMID 19682503), and the 2018 diagnostic evaluation examined thyrotropin responses to GHRP-2 in patients being assessed for thyrotropin-producing adenomas (PMID 29973439). A 2010 study reported the counter-example that GHRP-2 did not stimulate arginine vasopressin secretion in healthy men (PMID 19907099).

Appetite as a measurable effect

Increased eating is an effect that may be desirable or undesirable depending on context; in healthy men, the study reported that GHRP-2 increased food intake (PMID 15699539), while in neonatal chicks GHRP-2 and chicken ghrelin instead inhibited food intake (PMID 12393062).

Limits of the evidence in Module 4

No paper in this verified set reports long-term human safety, repeated-administration tolerability, interactions with other drugs, use in pregnancy, or outcomes in people with cardiovascular, metabolic or oncological disease. Absence of a reported adverse event in a short diagnostic study is not evidence that the event does not occur; it usually means it was not measured.

Module 5: Pharmacokinetics Where Data Exist

Pharmacokinetic detail is the thinnest part of this evidence base. The clearest signal comes indirectly from formulation chemistry: a 2015 study synthesised a mono-PEGylated GHRP-2 and investigated its biological activity (PMID 25761386) — PEGylation is a standard strategy applied to small peptides whose native circulating persistence is short, so the existence of that work tells readers something about why chemists modified the molecule at all.

Route and setting can also be read from the diagnostic studies: GHRP-2 has been used as a single-administration provocative test agent in patients with hypothalamic-pituitary disorder (PMID 35795807) and in children whose GH response to GHRP-2 was characterised (PMID 20662346), which is consistent with a rapid, short-lived hormonal response rather than a sustained exposure model. The 2004 development profile is the appropriate primary source for the compound's formulation and development status (PMID 15230633).

Limits of the evidence in Module 5

This course states no half-life, no bioavailability figure and no clearance value, because the verified papers listed here do not supply them within the scope summarised. Any specific pharmacokinetic number encountered elsewhere should be traced back to a named primary source before it is trusted.

Module 6: Regulatory Status, Stated Factually

Approved and clinical use

GHRP-2 under the generic name pralmorelin was carried through pharmaceutical development as a growth hormone-releasing peptide, as documented in the 2004 development profile (PMID 15230633). Its subsequent clinical footprint in the published literature is as a diagnostic test agent rather than a treatment: Japanese clinical studies used the GHRP-2 test to assess hypothalamic-pituitary disorder (PMID 35795807) and to evaluate suspected thyrotropin-producing pituitary adenomas (PMID 29973439).

Research-use-only material

In the United States there is no FDA-approved GHRP-2 drug product for therapeutic use. Material labelled "research use only" or "not for human consumption" is, by that label, sold for laboratory purposes and is not an approved medicine; such labelling does not make a substance a verified, tested or quality-assured pharmaceutical.

Compounding

Under the US Federal Food, Drug, and Cosmetic Act, a bulk drug substance used in pharmacy compounding generally must be a component of an FDA-approved drug, be the subject of an applicable USP or NF monograph, or appear on FDA's list of bulk drug substances that may be used in compounding. Growth hormone secretagogue peptides have attracted FDA attention in this area, and the agency has publicly discussed categorising certain peptides as raising safety concerns for compounding. Anti-doping context is separate again: growth hormone secretagogues are prohibited substances in sport under the World Anti-Doping Code.

This section describes publicly stated regulatory facts for educational purposes and is not legal advice; rules differ by country and change over time.

Limits of the evidence in Module 6

Regulatory status is jurisdictional and time-sensitive. A compound used as an approved diagnostic in one country is not thereby approved — for any purpose — in another, and none of the verified studies above speaks to the legality of obtaining or possessing the peptide anywhere.

What the Studies Did Not Test

Reading the whole set together, the gaps are as informative as the findings:

1. Long-term administration. The human papers here are single-administration diagnostic and physiology studies (PMID 35795807, PMID 19907099), not multi-week or multi-year treatment trials.
2. Body composition, strength and recovery. No verified study measured lean mass, fat mass, muscle strength, tendon or wound healing, or sleep architecture.
3. Healthy adults seeking performance or anti-ageing outcomes. The healthy-volunteer work measured food intake (PMID 15699539) and vasopressin (PMID 19907099), not performance endpoints.
4. Clinical translation of cell-culture findings. The granulosa-cell inflammation result was an in vitro observation (PMID 27548147) and was not tested in patients.
5. Comparative and combination work. No verified study here compared GHRP-2 head-to-head with other secretagogues over time or examined combinations.
6. Product quality. Nothing in this literature speaks to the identity, purity or sterility of any material circulating outside a regulated pharmaceutical supply chain.

A fair one-sentence summary of the evidence: GHRP-2 is a well-characterised ghrelin-receptor-directed pituitary test agent whose short-term hormonal and appetite effects have been reported in several models, while its long-term effects in healthy people remain untested in the literature reviewed here.

References

• Clinical Usefulness of the Growth Hormone-Releasing Peptide-2 Test for Hypothalamic-Pituitary Disorder (Journal of the Endocrine Society, 2022)
• Evaluation of growth hormone-releasing peptide-2 for diagnosis of thyrotropin-producing pituitary adenomas (Endocrine Journal, 2018)
• Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN (Drugs in R&D, 2004)
• Growth Hormone Releasing Peptide-2 Attenuation of Protein Kinase C-Induced Inflammation in Human Ovarian Granulosa Cells (International Journal of Molecular Sciences, 2016)
• GH-releasing peptide-2 does not stimulate arginine vasopressin secretion in healthy men (Endocrine Journal, 2010)
• Synthesis of Mono-PEGylated Growth Hormone Releasing Peptide-2 and Investigation of its Biological Activity (AAPS PharmSciTech, 2015)
• Growth hormone response to GH-releasing peptide-2 in children (Journal of Pediatric Endocrinology & Metabolism, 2010)
• Growth hormone-releasing peptide-2 stimulates secretion and synthesis of adrenocorticotropic hormone in mouse pituitary (Regulatory Peptides, 2009)
• Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men (Journal of Clinical Endocrinology and Metabolism, 2005)
• Growth hormone response to growth hormone-releasing peptide-2 in growth hormone-deficient little mice (Clinics, 2012)
• Chicken ghrelin and growth hormone-releasing peptide-2 inhibit food intake of neonatal chicks (European Journal of Pharmacology, 2002)
• General pharmacology of KP-102 (GHRP-2), a potent growth hormone-releasing peptide (Arzneimittel-Forschung, 2004)